pharma
Amarin Neuroscience
Amarin Neuroscience Ltd
NovaPharmaNews editorial coverage mentioning Amarin Neuroscience — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- GB
- Programs
- 0
- Drugs
- 0
- Patents
- 11
News & analysis
NovaPharmaNews articles mentioning Amarin Neuroscience — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Amarin Neuroscience — regulatory, clinical, and market analysis.
Generic Drugmakers Gain Key Victory in ‘Skinny Label’ Patent Case
The US Supreme Court unanimously ruled that Hikma Pharmaceuticals did not infringe Amarin's patents in a skinny-label case, overturning a lower court decision. This decision makes generic drugmakers less vulnerable to lawsuits over skinny labels, preserving a key pathway for early market entry on unpatented indications.
STAT Supreme Court backs generic drugmaker in 'skinny labeling' case: Implications for pharma BD and investors
The U.S. Supreme Court unanimously ruled that Hikma Pharmaceuticals did not infringe Amarin's patents through its skinny-labeled generic version of Vascepa. This decision clarifies the Hatch-Waxman skinny-label safe harbor, reducing litigation risk for generic entrants and reshaping competitive dynamics for branded cardiovascular drugs.